Shi, Ping
Liu, Xin
Li, Ting
Sun, Fei-fei
Liu, Yan-ping
Liu, Shu-qin
Gao, Xiao-meng
Ma, Ya-ping
Fu, Yao
Funding for this research was provided by:
National Major Science and Technology Projects of China (2020ZX09201-018, 2017ZX09304-024)
Article History
Accepted: 28 October 2021
First Online: 30 November 2021
Declarations
:
: This work was supported by grants from the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2020ZX09201-018, 2017ZX09304-024).
: PS, XL, TL, FS, YL, SL, XG, YM, YF, and YC have no conflicts of interest that are directly relevant to the content of this article.
: This clinical study protocol was approved by the Medical Ethics Committee at the Affiliated Hospital of Qingdao University, and the trial was registered with the Clinical Trial Registry (trial ID: NCT04877106).
: All subjects provided written informed consent.
: All authors give the publisher the permission to publish the work. Subjects signed informed consent regarding publishing their data.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: All authors completed this study together. Xin Liu and Ping Shi planned and drafted the paper and contributed to data quality control, analysis, and interpretation. Ting Li and Fei-fei Sun recorded the AEs and compiled statistics on AEs. Yan-ping Liu and Shu-qin Liu contributed to data collection. Yu Cao provided methodological guidance and support with data interpretation. All authors reviewed and revised the manuscript.